GO:0050220 prostaglandin-E synthase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050220 (prostaglandin-E synthase activity) catalyzes the isomerization of prostaglandin H2 (PGH2) to prostaglandin E2 (PGE2), a key terminal step in prostanoid biosynthesis.
• The best-characterized enzyme carrying this activity is microsomal prostaglandin E synthase-1 (mPGES-1, gene PTGES), a membrane-bound, glutathione-dependent isomerase.
• mPGES-1 is a validated therapeutic target in inflammation, cancer, and acute lung injury, with extensive patent and drug-discovery activity [3,4,5,6].
• The enzyme is induced by pro-inflammatory stimuli and functionally couples with cyclooxygenase-2 (COX-2) to drive PGE2 production [1,7].
• Beyond mammals, prostaglandin E synthase activity has been structurally and biochemically characterized in invertebrates such as Bombyx mori.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are powerful tools to dissect the causal role of PTGES and related genes in disease [1,2].
Description
Prostaglandin-E synthase activity (GO:0050220) is a molecular function that catalyzes the conversion of prostaglandin H2 (PGH2) into prostaglandin E2 (PGE2), a potent lipid mediator of inflammation, pain, fever, and tumor progression. This activity represents the terminal, rate-limiting step in the PGE2 biosynthetic pathway and is carried out by dedicated prostaglandin E synthases, most notably microsomal prostaglandin E synthase-1 (mPGES-1), which is encoded by the PTGES gene. Because PGE2 is a central driver of numerous pathological states, understanding the enzymes that produce it is of major biomedical importance [1,3]. Research on GO:0050220 has accelerated due to the recognition that mPGES-1 is a promising drug target that may avoid the gastrointestinal and cardiovascular side effects associated with broad COX inhibition [3,4]. The enzyme is a membrane-bound, glutathione-dependent isomerase that functionally couples with cyclooxygenase-2 (COX-2) to efficiently channel PGH2 toward PGE2. Its expression is strongly induced by pro-inflammatory cytokines and is elevated in many cancers and inflammatory diseases [1,4]. In this article, we provide a research-grade overview of prostaglandin-E synthase activity, covering its definition, catalytic mechanism, key genes, disease relevance, and the CRISPR-based models and methodologies used to study it. All statements are grounded in the verified literature cited by number.
prostaglandin-E synthase activity At A Glance
| GO ID | GO:0050220 |
|---|---|
| GO term | prostaglandin-E synthase activity |
| Ontology | molecular_function |
| Synonym | PGE2 isomerase activity; PGH-PGE isomerase activity; endoperoxide isomerase activity; prostaglandin-H2 E-isomerase activity |
| Major function | Catalyzes the isomerization of prostaglandin H2 (PGH2) to prostaglandin E2 (PGE2) |
| Representative enzyme | Microsomal prostaglandin E synthase-1 (mPGES-1), encoded by PTGES |
| Cofactor requirement | Glutathione (GSH)-dependent for mPGES-1 |
| Subcellular location | Microsomal membranes (endoplasmic reticulum and nuclear envelope) |
| Pathophysiological role | Inflammation, cancer, pain, fever, acute lung injury, neuroinflammation |
What Is GO:0050220?
According to the Gene Ontology, prostaglandin-E synthase activity (GO:0050220) is defined as the catalysis of the reaction: prostaglandin H(2) = prostaglandin E(2). In other words, it is the enzymatic isomerization of the endoperoxide PGH2 to the hydroxyketone PGE2. This activity is synonymous with terms such as PGE2 isomerase, PGH-PGE isomerase, and endoperoxide isomerase activity. It is a molecular function that resides in the broader context of prostanoid metabolism and is essential for the production of PGE2, a key signaling lipid.
Why Is prostaglandin-E synthase activity Important in Cell Biology?
Prostaglandin-E synthase activity is critically important because it produces PGE2, a lipid mediator that regulates inflammation, pain, fever, and cancer progression. The enzyme mPGES-1, which carries this activity, is a validated therapeutic target for inflammatory diseases and cancer, and its inhibition is actively pursued as an alternative to COX-2 inhibition [3,4,5]. Understanding this activity at the molecular level informs drug discovery and the development of precision medicine approaches.
• Produces PGE2, a major pro-inflammatory and pro-tumorigenic lipid mediator.
• mPGES-1 is a promising drug target for inflammation and cancer, with numerous patents and inhibitors under development [3,4,5].
• Inhibition of mPGES-1 ameliorates acute lung injury in preclinical models.
• mPGES-1 is implicated in neuroinflammatory disorders, including Alzheimer's and Parkinson's diseases.
• The enzyme functionally couples with COX-2 to drive PGE2 synthesis in pathological states.
• Prostaglandin E synthase activity is conserved across species, including insects, enabling comparative studies.
• Targeting this activity may reduce PGE2-driven immunosuppression in the tumor microenvironment.
• Genetic and pharmacological tools targeting PTGES are essential for dissecting its causal roles [1,2].
What Happens During prostaglandin-E synthase activity?
Substrate binding and isomerization
In simple terms: The enzyme grabs PGH2 and rearranges its atoms to form PGE2.
Prostaglandin-E synthase activity begins with the binding of the substrate prostaglandin H2 (PGH2), an unstable endoperoxide intermediate produced by cyclooxygenases. The enzyme catalyzes an isomerization reaction that converts the endoperoxide bridge of PGH2 into a hydroxyketone, yielding prostaglandin E2 (PGE2). This reaction is highly specific and represents the terminal step in PGE2 biosynthesis.
Glutathione-dependent catalysis
In simple terms: A small molecule called glutathione helps the enzyme do its job.
For microsomal prostaglandin E synthase-1 (mPGES-1), the catalytic mechanism is glutathione (GSH)-dependent. GSH acts as a cofactor that facilitates the rearrangement of the endoperoxide, and the enzyme belongs to the MAPEG (membrane-associated proteins in eicosanoid and glutathione metabolism) superfamily. This dependence on GSH distinguishes mPGES-1 from other PGE synthases.
Coupling with COX-2
In simple terms: The enzyme works together with COX-2 to efficiently make PGE2.
mPGES-1 functionally couples with cyclooxygenase-2 (COX-2), the enzyme that produces PGH2. This coupling ensures efficient channeling of PGH2 to PGE2, particularly under inflammatory conditions where both enzymes are co-induced. This functional cooperation is a key feature of the PGE2 biosynthetic pathway.
Regulation of enzyme expression
In simple terms: The amount of the enzyme goes up or down depending on signals.
The expression of mPGES-1 is induced by pro-inflammatory cytokines such as interleukin-1 beta and tumor necrosis factor alpha, and is upregulated in many pathological conditions [1,7]. This inducible expression is a major point of regulation for prostaglandin-E synthase activity.
Key Genes Involved in GO:0050220 prostaglandin-E synthase activity
The following genes and proteins are directly or indirectly involved in prostaglandin-E synthase activity and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTGES | Encodes mPGES-1, the main enzyme with prostaglandin-E synthase activity | Central to PGE2 biosynthesis; target for inflammation and cancer |
| PTGS2 | Encodes COX-2, which produces the substrate PGH2 | Couples with mPGES-1 for efficient PGE2 production |
| PTGS1 | Encodes COX-1, a constitutive source of PGH2 | Provides substrate for PGE2 synthesis in some tissues |
| PTGES2 | Encodes mPGES-2, another PGE synthase | Alternative route for PGE2 production; less studied |
| PTGES3 | Encodes cytosolic PGE synthase (cPGES) | Constitutive PGE2 synthesis; may couple with COX-1 |
| HPGD | Encodes 15-hydroxyprostaglandin dehydrogenase, which degrades PGE2 | Regulates PGE2 levels; tumor suppressor in some cancers |
| SLCO2A1 | Encodes a prostaglandin transporter | Affects PGE2 availability and signaling |
| ABCC4 | Encodes a multidrug resistance protein that exports PGE2 | Influences extracellular PGE2 levels |
| PTGER1 | Encodes the EP1 receptor for PGE2 | Mediates PGE2 signaling in pain and cancer |
| PTGER2 | Encodes the EP2 receptor for PGE2 | Mediates PGE2 signaling in inflammation and cancer |
| PTGER3 | Encodes the EP3 receptor for PGE2 | Mediates PGE2 signaling in fever and pain |
| PTGER4 | Encodes the EP4 receptor for PGE2 | Mediates PGE2 signaling in immune modulation |
| NFKB1 | Transcription factor that drives PTGES expression | Links inflammation to PGE2 production |
| IL1B | Pro-inflammatory cytokine that induces PTGES | Upregulates mPGES-1 in inflammatory diseases |
| TNF | Pro-inflammatory cytokine that induces PTGES | Upregulates mPGES-1 in inflammatory diseases |
| GPX4 | Glutathione peroxidase that regulates ferroptosis and interacts with PGE2 pathway | Potential crosstalk with PGE2 metabolism |
| P23 | Chaperone protein that stabilizes GPX4 and negatively regulates ferroptosis | May influence PGE2-related oxidative stress |
How Is prostaglandin-E synthase activity Regulated?
Prostaglandin-E synthase activity is regulated at multiple levels. The expression of PTGES (mPGES-1) is induced by pro-inflammatory cytokines such as IL-1 beta and TNF, which activate transcription factors including NF-kB. The enzyme is also regulated by post-translational modifications and its interaction with COX-2, which provides the substrate PGH2. Additionally, glutathione availability affects catalytic activity, as mPGES-1 is a glutathione-dependent enzyme. In cancer, PTGES is often overexpressed, contributing to elevated PGE2 levels that promote tumor progression and immune evasion.
prostaglandin-E synthase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTGES | Inflammation, cancer, neuroinflammation | PTGES knockout mice; cancer cell lines with PTGES KO [1,4] |
| PTGS2 | Inflammation, cancer, pain | PTGS2 knockout mice; COX-2 inhibitors |
| HPGD | Cancer, prostaglandin degradation | HPGD knockout or overexpression models |
| GPX4 | Ferroptosis, oxidative stress | GPX4 knockout or point-mutation models |
| P23 | Ferroptosis regulation | P23 knockout or overexpression models |
Inflammation and neuroinflammatory disorders
Prostaglandin-E synthase activity and its product PGE2 are central to inflammation and neuroinflammation. mPGES-1 is induced in activated microglia and astrocytes and contributes to neuroinflammatory disorders such as Alzheimer's disease and Parkinson's disease. Inhibition of mPGES-1 reduces PGE2 production and attenuates inflammatory responses in preclinical models [1,6].
Cancer
Elevated prostaglandin-E synthase activity and PGE2 levels are observed in many cancers, where they promote cell proliferation, angiogenesis, and immune suppression. mPGES-1 is considered a targeted therapy candidate in cancer treatment, and its inhibition may complement or replace COX-2 inhibitors. Preclinical studies have shown that mPGES-1 inhibition reduces tumor growth and modulates the tumor microenvironment.
Acute lung injury
Inhibition of mPGES-1 ameliorates acute lung injury in mice, suggesting that prostaglandin-E synthase activity contributes to pulmonary inflammation and injury. This highlights the therapeutic potential of targeting this activity in acute inflammatory conditions.
Ferroptosis and oxidative stress
Recent studies have linked PGE2 metabolism to ferroptosis, a form of regulated cell death. The chaperone protein P23 negatively regulates ferroptosis by blocking GPX4 degradation, and this pathway may intersect with prostaglandin-E synthase activity through shared lipid metabolism. Further research is needed to fully elucidate these connections.
From prostaglandin-E synthase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PTGES loss reduce PGE2 production and inflammation? | PTGES knockout cell lines or mice [1,6] |
| Does a specific point mutation in PTGES affect catalytic activity? | Point-mutation knock-in cell lines |
| Can tagged mPGES-1 be used to study protein interactions? | Knock-in of epitope-tagged PTGES |
| Does overexpression of PTGES drive tumorigenesis? | PTGES overexpression cell lines and xenografts |
| What is the role of mPGES-1 in neuroinflammation? | PTGES knockout mice in neuroinflammation models |
| Can CRISPR screening identify regulators of PGE2 production? | Genome-wide CRISPR knockout library screening |
How to Study the prostaglandin-E synthase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS | PGE2 production from PGH2 | Enzyme activity assays |
| EIA | PGE2 levels in cell culture or tissue | Inflammation studies |
| qRT-PCR | PTGES mRNA expression | Gene regulation studies |
| RNA-seq | Transcriptome-wide changes | Pathway analysis |
| Western blot | mPGES-1 protein levels | Expression validation |
| Immunofluorescence | Subcellular localization of mPGES-1 | Organelle studies |
| CRISPR knockout | Loss-of-function phenotypes | Causal gene studies [1,2] |
| CRISPR knock-in | Tagged or mutant protein expression | Structure-function studies |
Biochemical assays for prostaglandin-E synthase activity
Enzyme activity can be measured using purified enzyme or cell lysates by monitoring the conversion of PGH2 to PGE2 via liquid chromatography-mass spectrometry (LC-MS) or enzyme immunoassay (EIA). These assays are essential for characterizing inhibitors and mutants.
Gene expression analysis
Quantitative RT-PCR and RNA-seq are used to measure PTGES mRNA levels in response to inflammatory stimuli or genetic perturbations. This helps determine how prostaglandin-E synthase activity is regulated at the transcriptional level.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify protein-protein interactions of mPGES-1 and post-translational modifications. Affinity purification coupled with mass spectrometry is useful for studying the mPGES-1 interactome.
CRISPR-based functional genomics
CRISPR knockout, knock-in, and overexpression models enable causal interrogation of PTGES and related genes in disease models [1,2]. Pooled CRISPR screens can identify modifiers of PGE2 production and ferroptosis.
How CRISPR Can Be Used to Study GO:0050220 prostaglandin-E synthase activity
Knockout
CRISPR-Cas9 knockout of PTGES eliminates prostaglandin-E synthase activity, allowing researchers to assess its contribution to PGE2 production and disease phenotypes [1,6]. PTGES knockout mice and cell lines are valuable for validating drug targets.
Point Mutation
Point mutations can be introduced into PTGES to study catalytic residues or regulatory sites. For example, mutating the glutathione-binding site can abolish enzymatic activity, providing insights into the mechanism.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) into the endogenous PTGES locus enables studies of protein localization, interactions, and dynamics under native regulation. Knock-in of disease-associated variants can model human genetics.
Overexpression
Overexpression of PTGES using lentiviral or transgenic systems increases PGE2 production and can drive inflammatory or tumorigenic phenotypes, useful for gain-of-function studies.
How EDITGENE Supports prostaglandin-E synthase activity Research
Researchers studying prostaglandin-E synthase activity-related genes often need to determine whether a candidate gene is causally involved in PGE2 production, inflammation, or cancer. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for prostaglandin-E synthase activity research.
Frequently Asked Questions About prostaglandin-E synthase activity
What is prostaglandin-E synthase activity?
Prostaglandin-E synthase activity (GO:0050220) is the enzymatic conversion of prostaglandin H2 (PGH2) to prostaglandin E2 (PGE2), a key lipid mediator of inflammation and cancer.
What genes are involved in prostaglandin-E synthase activity?
The main gene is PTGES, which encodes microsomal prostaglandin E synthase-1 (mPGES-1). Other related genes include PTGS2 (COX-2), PTGES2, PTGES3, and PGE2 receptors.
What is the role of mPGES-1 in inflammation?
mPGES-1 is induced by inflammatory cytokines and produces PGE2, which drives inflammation, pain, and fever. Its inhibition is a therapeutic strategy for inflammatory diseases [1,3].
How is prostaglandin-E synthase activity measured?
It is typically measured by incubating enzyme preparations with PGH2 and quantifying PGE2 production using LC-MS or enzyme immunoassay.
Is mPGES-1 a drug target?
Yes, mPGES-1 is a validated drug target for inflammation and cancer, with numerous inhibitors and patents under development [3,4,5].
What diseases are associated with prostaglandin-E synthase activity?
It is associated with inflammatory diseases, cancer, neuroinflammatory disorders, and acute lung injury [1,4,6].
Can CRISPR be used to study prostaglandin-E synthase activity?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to study PTGES function and its role in disease [1,2].
What is the difference between mPGES-1 and COX-2?
COX-2 produces the substrate PGH2, while mPGES-1 converts PGH2 to PGE2. They functionally couple in the PGE2 biosynthetic pathway.
Are there species differences in prostaglandin-E synthase activity?
Yes, prostaglandin E synthase has been characterized in various species, including Bombyx mori, showing structural and functional conservation.
How can I create a PTGES knockout cell line?
EDITGENE provides custom CRISPR knockout services for PTGES and related genes, with validated clones and functional characterization [1,6].
Conclusion
Prostaglandin-E synthase activity (GO:0050220) is a critical enzymatic function that produces PGE2, a key mediator of inflammation, cancer, and neuroinflammation. The enzyme mPGES-1, encoded by PTGES, is a validated therapeutic target with extensive drug discovery efforts [3,4,5]. Understanding its mechanism, regulation, and disease relevance is essential for developing new treatments. CRISPR-based models, including knockout, point mutation, knock-in, and overexpression, provide powerful tools to dissect the causal roles of PTGES and related genes. EDITGENE offers comprehensive services to support this research, from custom cell line generation to CRISPR library screening and bioinformatics analysis.
References
- 1. Sluter MN et al.. 2023. The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders.. Exp Biol Med (Maywood) 248(9):811-819 PMID: 37515545
- 2. Chen J et al.. 2025. P23 acts as a negative regulator of ferroptosis in NSCLC by blocking GPX4 degradation via chaperone-mediated autophagy.. Mol Cancer 24(1):234 PMID: 41039570
- 3. Psarra A et al.. 2017. Microsomal prostaglandin E(2) synthase-1 inhibitors: a patent review.. Expert Opin Ther Pat 27(9):1047-1059 PMID: 28627961
- 4. Larsson K et al.. 2015. Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment.. Prostaglandins Other Lipid Mediat 120:161-5 PMID: 26100239
- 5. Dos Santos Nascimento IJ et al.. 2022. Computer-Aided Drug Design of Anti-inflammatory Agents Targeting Microsomal Prostaglandin E(2) Synthase-1 (mPGES-1).. Curr Med Chem 29(33):5397-5419 PMID: 35301943
- 6. Gurusamy M et al.. 2021. Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice.. J Transl Med 19(1):340 PMID: 34372885
- 7. Samuelsson B et al.. 2007. Membrane prostaglandin E synthase-1: a novel therapeutic target.. Pharmacol Rev 59(3):207-24 PMID: 17878511
- 8. Yamamoto K et al.. 2021. Investigation of the Substrate-Binding Site of a Prostaglandin E Synthase in Bombyx mori.. Protein J 40(1):63-67 PMID: 33403608
